Solvotrin Therapeutics Competitors and Similar CompaniesClear all

Solvotrin Therapeutics's competitors and similar companies include Vertex Pharmaceuticals, CSL Behring and Alembic Pharmaceuticals.

	Solvotrin Therapeutics Solvotrin Therapeutics is a drug development company focused on chemical modifications of known drugs.	Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.	CSL Behring CSL Behring is a provider of life-saving medicines.	Alembic Pharmaceuticals Alembic Pharmaceuticals is a company that manufactures branded formulations, international generics, and APIs (active pharmaceutical ingredients).
Founding Date	Founding Date 2009	Founding Date 1989	Founding Date 1904	Founding Date 1907
Type	Type Private	Type Public	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations IE HQ	Locations Boston, US HQ St Leonards, AU Wien, AT Bruxelles, BE São Paulo, BR Toronto, CA Praha, CZ see more	Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more	Locations Vadodara, IN HQ Mumbai, IN Vadodara, IN
Employees	Employees 225% increase	Employees 5,40013% increase	Employees 7,5692% decrease	Employees 14,8582% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $9.9b (FY, 2023)	Revenue (est.) $7.9b (FY, 2020)	Revenue (est.) ₹61.1b (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods $1.3b (FY, 2023)	Cost of goods N/A	Cost of goods ₹19.3b (FY, 2024)
Gross profit	Gross profit N/A	Gross profit $8.6b (FY, 2023)	Gross profit $4.5b (FY, 2020)	Gross profit ₹43b (FY, 2024)
Net income	Net income N/A	Net income $3.6b (FY, 2023)	Net income N/A	Net income ₹6.2b (FY, 2024)
Funding
Total funding raised	Total funding raised $ 4.4m	Total funding raised $ 2.4m	Total funding raised N/A	Total funding raised N/A